(Q45880613)

17 December 2017

review article

1 reference

title

The potential impact of recombinant factor VIII on hemophilia care and the demand for blood and blood products (English)

1 reference

17 December 2017

main subject

hemophilia

0 references

Coagulation factor VIII

0 references

author name string

VanAken WG

series ordinal

1

1 reference

17 December 2017

publication date

1 January 1997

1 reference

17 December 2017

Transfusion Medicine Reviews

published in

1 reference

17 December 2017

volume

11

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

6-14

1 reference

17 December 2017

Production of High-Potency Concentrates of Antihemophilic Globulin in a Closed-Bag System

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Characterization of the human factor VIII gene

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Expression of active human factor VIII from recombinant DNA clones

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Structure of human factor VIII

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Molecular cloning of a cDNA encoding human antihaemophilic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Summary of clinical experience with recombinant factor VIII products--Kogenate

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

1 reference

7 January 2021

Preparation of antihemophilic factor and fibronectin from human plasma cryoprecipitate

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Life expectancy of Swedish haemophiliacs, 1831-1980.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Two decades of haemophilia treatment in the Netherlands, 1972-92.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Chronic hepatitis in haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Hepatitis C infection and viremia in Dutch hemophilia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. Canadian Hemophilia Clinic Directors Group

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Inactivation of viruses in blood and plasma products

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Pooled plasma derivatives and Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Why do so many haemophilia A patients develop an inhibitor?

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Current status of clinical studies of recombinant factor VIII (recombinate) in patients with hemophilia A. Recombinate Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

Enhanced thrombin sensitivity of a factor VIII-heparin cofactor II hybrid

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2897%2980005-3

7 January 2021

10.1016/S0887-7963(97)80005-3

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017